CMS
VRTX icon

Capital Market Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Market Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$298K Sell
670
-350
-34% -$161K 0.21% 99
2025
Q1 		$495K Buy
1,020
+20
+2% +$9.32K 0.33% 60
2024
Q4 		$403K Sell
1,000
-38
-4% -$17.6K 0.23% 93
2024
Q3 		$483K Buy
1,038
+5
+0.5% +$2.4K 0.29% 70
2024
Q2 		$484K Sell
1,033
-124
-11% -$53.8K 0.31% 65
2024
Q1 		$484K Buy
1,157
+207
+22% +$87.5K 0.37% 61
2023
Q4 		$387K Sell
950
-12
-1% -$4.43K 0.34% 73
2023
Q3 		$332K Buy
962
+84
+10% +$29.4K 0.33% 78
2023
Q2 		$309K Buy
+878
New +$296K 0.29% 89
2023
Q1 		– Sell
-870
Closed -$251K – 132
2022
Q4 		$251K Hold
870
– – 0.27% 104
2022
Q3 		$252K Hold
870
– – 0.28% 97
2022
Q2 		$245K Hold
870
– – 0.26% 108
2022
Q1 		$227K Buy
+870
New +$206K 0.2% 132

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Market Strategies's VRTX Position: Q2 2025 in Review

Capital Market Strategies reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2025, selling an estimated $161K and leaving 670 shares worth $298K. The position accounts for 0.21% of the portfolio, ranked #99.

Capital Market Strategies first reported a position in VRTX in Q1 2022 and has held it in 13 quarters since. The position peaked at $495K in Q1 2025. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Capital Market Strategies held 670 shares of Vertex Pharmaceuticals worth $298K as of Q2 2025.
  • Capital Market Strategies sold 350 Vertex Pharmaceuticals shares in Q2 2025, an estimated $161K.
  • Vertex Pharmaceuticals made up 0.21% of Capital Market Strategies's portfolio in Q2 2025, its #99 holding.
  • Capital Market Strategies first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Capital Market Strategies's Vertex Pharmaceuticals position peaked at $495K in Q1 2025.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Capital Market Strategies's 13F filing for Q2 2025, filed 2 Jul 2025.